# DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

> **NCT06173310** · NA · RECRUITING · sponsor: **Ohio State University** · enrollment: 50 (estimated)

## Conditions studied

- Borderline-resectable Pancreatic Cancer

## Interventions

- **DEVICE:** Point-of-care Portable Perfusion Phantom (P4)

## Key facts

- **NCT ID:** NCT06173310
- **Lead sponsor:** Ohio State University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-10
- **Primary completion:** 2029-03
- **Final completion:** 2029-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06173310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06173310, "DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06173310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*